Sideroblastic anemia diagnosis and management

Hematology/Oncology Clinics of North America

Volumn 28, Issue 4, 2014, Pages 653-670

  Bottomley, Sylvia S ^a   Fleming, Mark D ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Heme synthesis; Ineffective erythropoiesis; Iron overload; Iron sulfur clusters; Mitochondrial iron metabolism; Myelodysplastic syndrome; Ring sideroblasts; Sideroblastic anemia

Indexed keywords

HEMOGLOBIN; TRANSCRIPTION FACTOR GATA;

ATAXIA; CEREBELLUM HYPOPLASIA; CHILDHOOD CANCER; COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; GENETIC VARIABILITY; HEMATOPOIETIC TISSUE; HEME SYNTHESIS; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; INTESTINE ABSORPTION; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; LIVER FUNCTION; PEARSON SYNDROME; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REVIEW; SIDEROBLASTIC ANEMIA; SPLENECTOMY; SYSTEMATIC REVIEW; X CHROMOSOME INACTIVATION; X LINKED SIDEROBLASTIC ANEMIA; ANEMIA, SIDEROBLASTIC; COMPLICATION; DISEASE MANAGEMENT;

ANEMIA, SIDEROBLASTIC; DISEASE MANAGEMENT; HUMANS; IRON OVERLOAD;

EID: 84904806036     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.04.008     Document Type: Review

References (100)

1. Mollin D.L. Sideroblasts and sideroblastic anaemia. Br J Haematol 1965, 11:41-48.
2. Bottomley S.S. Sideroblastic anemias. Wintrobe's clinical hematology 2014, 643-661. Lippincott Williams & Wilkins Health, Philadelphia. 13th edition. J.P. Greer, D.A. Arbor, B. Glader (Eds.).
3. Bottomley S.S., Fleming M.D. Sideroblastic anemias: molecular basis, pathophysiology and clinical aspects. Handbook of porphyrin science: with applications to chemistry, physics, materials science, engineering, biology and medicine 2013, vol. 29:43-87. World Scientific Publishing, Hackensack (NJ).
4. Bergmann A.K., Campagna D.R., McLoughlin S.M., et al. Systematic molecular analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010, 54(2):273-278.
5. Rose C., Oudin C., Fournier M., et al. A new ALAS2 mutation inducing a male lethal X-linked sideroblastic anemia. Blood 2013, 122(21):2199. [abstract].
6. Busque I., Mio R., Mattioli J., et al. Non-random X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 1996, 88(1):59-65.
7. Liu G., Guo S., Kang H., et al. Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship. Haematologica 2013, 98(12):e158-e160.
8. Campagna D.R., deBie C.I., Schmitz-Abe K., et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol 2014, 89(3):315-319.
9. Kaneko K., Furuyama K., Fujiwara T., et al. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica 2014, 99(2):252-261.
10. Astner I., Schulze J.O., van den Heuvel J., et al. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis and its link to XLSA in humans. EMBO J 2005, 24(18):3166-3177.
11. Guernsey D.L., Jiang H., Campagna D., et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal-recessive congenital sideroblastic anemia. Nat Genet 2009, 41(6):651-653.
12. Kannengiesser C., Sanchez M., Sweeney M., et al. Missense SLC25A38 variations play an important role in autosomal recessive hereditary sideroblastic anemia. Haematologica 2011, 96(6):808-813.
13. Camaschella C., Campanella S., DeFalco L., et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007, 110(4):1353-1358.
14. Ye H., Jeong S.Y., Ghosh M.C., et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 2010, 120(5):1749-1761.
15. Rademakers L.H., Koningsberger J.C., Sorber C.W. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 1993, 23(2):130-138.
16. Lecha M., Puy H., Deybach J.C. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4:19-28.
17. Holme S.A., Worwood M., Anstey A.V., et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007, 110(12):4108-4110.
18. Pagon R.A., Bird T.D., Detter J.C., et al. Hereditary sideroblastic anaemia and ataxia: an X-linked recessive disorder. J Med Genet 1985, 22(4):267-273.
19. D'Hooghe M., Selleslag D., Mortier G., et al. X-linked sideroblastic anaemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation. Eur J Paediatr Neurol 2012, 16(6):730-735.
20. Bekri S., Kispal G., Lange H., et al. Human ABCB7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000, 96(9):3256-3264.
21. Wiseman D.H., May A., Jolles S., et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers and developmental delay (SIFD). Blood 2013, 122(1):112-123.
22. Rotig A., Cormier V., Blanch S., et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder of infancy. J Clin Invest 1990, 86(5):1601-1608.
23. Manea E.M., Leverger G., Bellmann F., et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. J Pediatr Hematol Oncol 2009, 31(12):947-951.
24. Gagne K.E., Ghazvinian R., Yuan D., et al. Pearson marrow pancreas syndrome in patients suspected to have diamond Blackfan anemia. Blood 2014, 10.1182/blood-2014-01-545830.
25. Bader-Meunier B., Mielot F., Breton-Gorius J., et al. Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears. Pediatr Res 1999, 46(2):158-162.
26. Rotig A., Gouargeron T., Chretien D., et al. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995, 4(8):1327-1330.
27. Bykhovskaya Y., Casas K., Mengesha E., et al. Missense mutation in pseudouridine synthase (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 2004, 74(6):1303-1308.
28. Patton J.R., Bykhovskaja Y., Mengesha E., et al. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem 2005, 280(20):19823-19828.
29. Suzuki T., Nagao A., Suzuki T. Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases. Annu Rev Genet 2011, 45:299-329.
30. Riley L.G., Menezes M.J., Rudinger-Thirion J., et al. Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia. Orphanet J Rare Dis 2013, 8:193-203.
31. Neufeld E.J., Fleming J.C., Tartaglini E., et al. Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. Blood Cells Mol Dis 2001, 27(1):135-138.
32. Bergmann A.K., Sahai I., Falcone J.F., et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009, 155(6):888-892.
33. Boros L.G., Steinkamp M.P., Fleming J.C., et al. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood 2003, 102(10):3556-3561.
34. Abboud M.R., Alexander D., Najjar S.S. Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associated with deficiency alpha-ketoglutarate dehydrogenase deficiency. J Pediatr 1985, 107(4):537-541.
35. Ducamp S., Kannengiesser C., Touati M., et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011, 32(6):590-597.
36. Kushner J.P., Lee G.R., Wintrobe M.M., et al. Idiopathic refractory sideroblastic anemia. Clinical and laboratory investigation of 17 patients and review of the literature. Medicine 1971, 50(3):139-159.
37. Swerdlow S.H., Campo E., Harris N.L., World Health Organization, et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon (France). 4th edition.
38. May A., Al-Sabah A.I., Lawless S.L. Acquired sideroblastic anemia unresponsive to pyridoxine caused by a somatic mutation I ALA synthase 2. Blood 2005, 106(11):988a-989a. [abstract].
39. Bottomley S.S., Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988, 25(4):282-302.
40. Sarkany R.P., Ross G., Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Brit J Dermatol 2006, 155(2):464-466.
41. Wulfert M., Kupper A.C., Tapprich C., et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndrome. Exp Hematol 2008, 36(5):577-586.
42. Gattermann N., Retzlaff S., Wang Y.L., et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit 1 of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997, 90(12):4961-4972.
43. Papaemmanuil E., Cazzola M., Boultwood J., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365(15):1384-1395.
44. Patnaik M.M., Lasho T.M., Hodnefield J.M., et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012, 119(2):569-572.
45. Visconte V., Makishima H., Jankowska A., et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012, 26(3):542-545.
46. Damm F., Kosmider O., Gelsi-Boyer V., et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012, 119(14):3211-3218.
47. Broseus J., Alpermann T., Wulfert M., et al. Age, JAK2(V617F) and SF2B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013, 27(9):1826-1831.
48. Boultwood J., Pellagatti A., Nikpour M., et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008, 3(4):e1970.
49. Nikpour M., Scharenberg C., Liu A., et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2013, 27(4):889-896.
50. Bottomley S.S., Wise P.D., Wasson E.G., et al. X-linked sideroblastic anemia in 10 female probands due to ALAS2 mutations and skewed X chromosome inactivation (Abstract). Am J Hum Genet 1998, 63:A352.
51. Aivado M., Gattermann N., Rong A., et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis 2006, 37(1):40-45.
52. Eichner E.R., Hillman R.S. The evolution of anemia in alcoholic patients. Am J Med 1971, 50(2):218-232.
53. Savage D., Lindenbaum J. Anemia in alcoholics. Medicine 1986, 65(5):322-338.
54. Bottomley S.S. Sideroblastic anaemia. Iron in biochemistry and medicine II 1980, 363-392. Academic Press, London. A. Jacobs, M. Worwood (Eds.).
55. Saini N., Jacobson N.O., Iha S., et al. The perils of not digging deep enough-uncovering a rare cause of acquired anemia. Am J Hematol 2012, 87(4):413-416.
56. Willekens C., Dumezy F., Boyer T., et al. Linezolid induces ring sideroblasts. Haematologica 2013, 98(11):e138-e140.
57. Kloss P., Xiong L., Shinabanger D.L., et al. Resistance mutations in 23 S rNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999, 294(1):93-101.
58. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 2006, 81(10):1371-1384.
59. Halfdanarson T.R., Kumar N., Hogan W.J., et al. Copper deficiency in celiac disease. J Clin Gastroenterol 2009, 43(2):162-164.
60. Cousins R.J. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985, 65(2):238-309.
61. Prodan C.I., Holland N.R., Wisdom P.J., et al. CNS demyelination associated with copper deficiency and hyperzincemia. Neurology 2002, 59(9):1453-1456.
62. Wahlin S., Harper P. The role of BMT in erythropoietic protoporphyria. Bone Marrow Transplant 2010, 45(2):393-394.
63. Casas K.A., Fischel-Ghodsian N. Mitochondrial myopathy and sideroblastic anemia. Am J Med Genet 2004, 125A(2):201-204.
64. Fernandez-Vizarra E., Berardinelli A., Valente L., et al. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anemia (MLASA). J Med Genet 2007, 44(3):173-180.
65. Sasarman F., Nishimura T., Thiffault I., et al. A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia. Hum Mutat 2012, 33(8):1201-1206.
66. Shahni R., Wedatilake Y., Cleary M.A., et al. A distinct mitochondrial myopathy, lactic acidosis and sideroblastic anemia (MLASA) phenotype associates with YARS2 mutations. Am J Med Genet A 2013, 161(9):2334-2338.
67. Nakajima J., Eminoglu T.F., Vatansever G., et al. A novel homozygous YARS2 mutation causes severe myopathy, lactic acidosis, and sideroblastic anemia 2. J Hum Genet 2014, 59(4):229-232.
68. Ricketts C.J., Minton J.A., Samuel J., et al. Thiamine-responsive megaloblastic anemia syndrome; long-term follow-up and mutation analysis of seven families. Acta Paediatr 2006, 95(1):99-104.
69. Cazzola M., Barosi G., Gobbi P.G., et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988, 71(2):305-312.
70. Germing U., Gattermann N., Aivado M., et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000, 108(4):724-728.
71. Byrd R.B., Cooper T. Hereditary-iron loading anemia with secondary hemochromatosis. Ann Intern Med 1961, 55:103-123.
72. Bottomley S.S. Sideroblastic anemia: death from iron overload. Hosp Pract 1991, 26(Suppl 3):55-56.
73. Cotter P.D., Rucknagel D.I., Bishop D.F. X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific δ-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood 1994, 84(11):3915-3924.
74. Aleali S.H., Castro O., Spencer R.P., et al. Sideroblastic anemia with splenic abscess and fatal thromboemboli after splenectomy. Ann Intern Med 1975, 83(5):661-663.
75. Byrne M.T., Bergmann A.K., Ruiz I., et al. Postsplenectomy thromboembolic disease. BMJ Case Rep 2010, 2010. pii:ber1220092514. 10.1136b/ber.12.2009.2514.
76. Bottomley S.S. Secondary iron overload disorders. Semin Hematol 1998, 35(1):77-86.
77. Bottomley S.S. Iron overload in sideroblastic and other non-thalassemic anemias. Hemochromatosis, pathophysiology, diagnosis and treatment 2000, 442-452. Cambridge University Press, Cambridge (United Kingdom). J.C. Barton, C.Q. Edwards (Eds.).
78. Hathway D., Harris J.W., Stenger R.J. Histopathology of the liver in pyridoxine-responsive anemia. Arch Pathol Lab Med 1967, 83(2):175-179.
79. Peto T.E.A., Pippard M.J., Weatherall D.J. Iron overload in mild sideroblastic anaemias. Lancet 1983, 1(8321):375-378.
80. Fairbanks V.F., Dickson E.R., Tompson M.E. Hereditary sideroblastic anemia. Hosp Pract 1991, 26(Suppl 3):53-55.
81. Barton J.C., Lee P.L. Disparate phenotype expression of ALAS2 B452H (nt 1407 G→A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis 2006, 36(3):342-346.
82. Cuijpers M.L., van Spronsen D.J., Muus P., et al. Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia. Int J Hematol 2011, 94(1):97-100.
83. Pippard M.J., Weatherall D.J. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading and response to iron chelation treatment, in β thalassemia intermedia and congenital sideroblastic anaemias. Haematologia (Budap) 1984, 17(1):17-24.
84. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13(9):1096-1101.
85. Tanno T., Miller J.L. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol 2010, 2010:358283.
86. Tanno T., Noel P., Miller J.L. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010, 17(3):184-190.
87. Tanno T., Porayette P., Sripichai O., et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009, 114(1):181-186.
88. Kautz L., Jung G., Nemeth E., et al. The erythroid factor erythroferrone and its role in iron homeostasis. Blood 2013, 122(21):4. [abstract].
89. Finch C. Regulation of iron balance in humans. Blood 1994, 84(6):1697-1702.
90. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007, 31(Suppl 3):S2-S6.
91. Leitch H.A., Leger C.S., Goodman T.A., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clinical Leukemia 2008, 2(3):205-211.
92. Neukirchen J., Fox F., Kundgen A., et al. Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 2012, 36(8):1067-1070.
93. Porter J.B., Lin K.H., Beris P., et al. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile iron for haemolytic or production anaemias. Eur J Haematol 2011, 87(4):338-348.
94. Steensma D.P., Gattermann N. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?. Best Pract Res Clin Haematol 2013, 26(4):431-444.
95. Viprakasit V., Gattermann N., Lee J.W., et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus 2013, 11(1):108-122.
96. Bennett J.M., MDS Foundation's Working Group on Transfusional Iron Overload Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(11):858-861.
97. Gattermann N. Pathophysiological and clinical aspects of iron chelation therapy in MDS. Curr Pharm Des 2012, 18(22):3222-3234.
98. French T.J., Jacobs P. Sideroblastic anaemia associated with iron overload treated by repeated phlebotomy. S Afr Med J 1976, 50(15):594-596.
99. Badawi M.A., Vickars L.M., Chase J.M., et al. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol 2010, 2010:164045.
100. Gattermann N., Finelli C., Della Porta M., et al. Haematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012, 97(9):1364-1371.